Core Viewpoint - Rosen Law Firm is reminding investors who purchased aTyr Pharma, Inc. common stock between January 16, 2025, and September 12, 2025, of the December 8, 2025, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought aTyr Pharma common stock during the specified period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The deadline to move the Court to serve as lead plaintiff is December 8, 2025, with the lead plaintiff representing other class members in the litigation [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - The firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions of dollars for investors [4]. Group 3: Case Background - The complaint alleges that defendants made misleading statements regarding the efficacy of Efzofitimod, particularly its ability to allow patients to taper steroid usage, leading to investor damages when the truth was revealed [5].

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired aTyr Pharma Inc. ("aTyr†or the "Company†) (NASDAQ: ATYR) common stock between January 16, 2025 and September 12, 2025, inclusive (the "Class Period†). aTyr investors have until December 8, 2025 to file a lead plaintiff motion. IF YOU SUFFERED A LOSS ON YOUR. ...

Core Points - aTyr Pharma, Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between January 16, 2025, and September 12, 2025 [1] - The lawsuit claims that aTyr misled investors regarding the efficacy of its drug Efzofitimod, particularly its ability to allow patients to taper steroid usage [2] - Following the announcement that the EFZO-FIT study did not meet its primary endpoint, aTyr's stock price plummeted by 83.2%, from $6.03 to $1.02 per share in one day [2] Case Details - The complaint alleges that the defendants made positive statements while concealing material adverse facts about the drug's efficacy [2] - The primary endpoint not being met was disclosed during an investor call on September 15, 2025, leading to significant stock price decline [2] - aTyr plans to engage with the FDA to determine the next steps after the disappointing study results [2] Next Steps - Investors who suffered losses during the relevant timeframe have until December 8, 2025, to request to be appointed as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years [4]

Core Viewpoint - A class action lawsuit has been filed against aTyr Pharma, Inc. regarding allegations of securities fraud and unlawful business practices following disappointing clinical trial results [2][4]. Group 1: Lawsuit Details - The class action lawsuit concerns whether aTyr and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until December 8, 2025, to request appointment as Lead Plaintiff if they purchased aTyr securities during the Class Period [2]. Group 2: Clinical Trial Results - On September 15, 2025, aTyr announced that the EFZO-FIT study, a Phase 3 trial for intravenous Efzofitimod in pulmonary sarcoidosis patients, did not meet its primary endpoint [4]. - Following the announcement of the trial results, aTyr's stock price fell by $5.01 per share, or 83.17%, closing at $1.01 per share [5]. Group 3: Company Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for class members [6].

Core Points - aTyr Pharma, Inc. is facing a class action lawsuit due to allegations of providing misleading statements regarding the efficacy of its drug Efzofitimod, particularly concerning its ability to allow patients to taper steroid usage completely [2][4] - The company's EFZO-FIT study did not meet its primary endpoint, leading to a significant drop in stock price from $6.03 to $1.02, a decline of 83.2% in one day [2][3] - Shareholders who purchased shares during the class period from January 16, 2025, to September 12, 2025, are encouraged to register for the class action, with a lead plaintiff deadline set for December 8, 2025 [3][4] Company Information - The Gross Law Firm is representing shareholders in the class action, emphasizing its commitment to protecting investors from deceit and fraud [4][5] - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4]

Core Viewpoint - aTyrPharma, Inc. is facing a class action lawsuit due to allegations of misleading investors regarding the efficacy of its drug candidate, Efzofitimod, during a clinical trial for pulmonary sarcoidosis [1][2]. Group 1: Allegations and Study Results - The lawsuit claims that aTyr's executives provided misleading information about the Phase 3 study's design and the drug's ability to allow patients to taper off steroids completely [2]. - On September 15, 2025, aTyr announced that the EFZO-FIT study did not meet its primary endpoint, specifically the change from baseline in mean daily OSC dose at week 48 [3]. - Following the announcement, aTyr's stock price plummeted from $6.03 per share on September 12, 2025, to $1.02 per share on September 15, 2025, marking an 83.2% decline in a single day [3]. Group 2: Legal Proceedings - Shareholders interested in participating in the class action must submit their papers to the court by December 8, 2025, to serve as lead plaintiff [4]. - The lead plaintiff will represent other class members in directing the litigation, but participation is not required to be eligible for recovery [4].

Core Points - aTyr Pharma, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between January 16, 2025, and September 12, 2025 [1] - The lawsuit claims that aTyr made misleading statements regarding the efficacy of its drug Efzofitimod, particularly its ability to allow patients to taper steroid usage [2] - The stock price of aTyr plummeted by 83.2%, from $6.03 per share on September 12, 2025, to $1.02 per share on September 15, 2025, following the announcement that the EFZO-FIT study did not meet its primary endpoint [2] Case Details - The complaint alleges that aTyr provided overly positive statements while concealing material adverse facts about Efzofitimod [2] - The EFZO-FIT study's failure to meet its primary endpoint was disclosed during an investor call on September 15, 2025, prompting the company to engage with the FDA for future steps [2] Next Steps - Investors who suffered losses during the specified timeframe have until December 8, 2025, to request appointment as lead plaintiff, although participation does not require this [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as a leading securities litigation firm in the U.S. [4]

Core Viewpoint - Law Offices of Frank R. Cruz is encouraging shareholders of aTyr Pharma Inc. to inquire about a potential securities fraud class action [1] Group 1 - The law firm is actively seeking shareholders of aTyr Pharma Inc. to participate in the inquiry regarding the alleged securities fraud [1] - The announcement indicates a growing concern among investors about the company's practices and potential legal implications [1]

Core Viewpoint - A class action lawsuit has been filed against aTyr Pharma, Inc. regarding allegations of securities fraud and unlawful business practices [2][4]. Group 1: Lawsuit Details - The lawsuit involves claims that aTyr and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until December 8, 2025, to request to be appointed as Lead Plaintiff if they purchased aTyr securities during the Class Period [2]. Group 2: Company Performance - On September 15, 2025, aTyr announced that its EFZO-FIT study did not meet its primary endpoint, leading to a significant drop in stock price [4]. - Following the announcement, aTyr's stock price fell by $5.01 per share, or 83.17%, closing at $1.01 per share [5]. Group 3: Company Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for class members [6].

Core Points - aTyr Pharma, Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between January 16, 2025, and September 12, 2025 [1] - The lawsuit claims that aTyr misled investors regarding the efficacy of its drug Efzofitimod, particularly its ability to allow patients to taper steroid usage [2] - The stock price of aTyr plummeted by 83.2%, from $6.03 on September 12, 2025, to $1.02 on September 15, 2025, following the announcement that the EFZO-FIT study did not meet its primary endpoint [2] Case Details - The complaint alleges that the defendants provided overly positive statements while concealing material adverse facts about the drug's efficacy [2] - The EFZO-FIT study's failure to meet its primary endpoint was disclosed during an investor call on September 15, 2025, prompting the stock price decline [2] - aTyr plans to engage with the FDA to determine the next steps after the disappointing study results [2] Next Steps - Investors who suffered losses during the relevant time frame have until December 8, 2025, to request to be appointed as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4] - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]